The TEL/AML1 chimeric gene is generated by the t(12;21) translocation in pre-B cell acute lymphoblastic leukemia. TEL/AML1 consists of the helix-loop-helix (HLH) dimerization domain from TEL and almost the entire of AML1, but loses the ETS DNA-binding domain from TEL. Dominant-negative effects of TEL/AML1 over wild-type-AML1 are believed to trigger the development of this type of leukemia. However, it could also be possible that TEL/AML1 affects wild-type-TEL's molecular and tumor suppressive functions through the HLH domain. To test this possibility, we first confirmed that TEL/AML1 associates with wild-type-TEL. TEL/AML1 neither bound to the ETS-binding consensus site nor repressed transcription through it. Regardless, this prevented wild-type-TEL-induced transcriptional repression. Moreover, TEL/AML1 concomitantly inhibited wild-type-TEL-induced growth suppression and wild-type-AML1-mediated transforming activity in NIH3T3 cells. All these data indicate that TEL/AML1 exerts dominant-interfering effects on both AML1 and TEL, and that expression of TEL/AML1 could result in inactivation of TEL's tumor suppressive functions in t(12;21)-carrying leukemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bbrc.2004.07.169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential molecular mechanisms of ETV6-RUNX1-positive B progenitor cell cluster in acute lymphoblastic leukemia revealed by single-cell RNA sequencing.
PeerJ
November 2024
Neurosurgery Department, Jinzhou Central Hospital, Jinzhou, China.
Article Synopsis
- The study aimed to investigate the immune landscape and immune cell roles in the progression of acute lymphoblastic leukemia (ALL), focusing particularly on the ETV6-RUNX1 genetic alteration common in childhood cases.
- Using advanced techniques like single-cell RNA sequencing, researchers analyzed B progenitor cells from bone marrow samples, identifying specific gene expressions and pathways that may drive rapid cell cycle progression in ALL.
- Results highlighted distinct clusters of B progenitor cells, particularly one with amplified genes on chromosome 6p that were linked to increased cell cycle activity, underscoring the complexity of immune interactions in the disease's progression.
Outcomes in patients with ETV6::RUNX1 or high-hyperdiploid B-ALL treated in the St. Jude Total Therapy XV/XVI studies.
Blood
January 2025
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement.
View Article and Find Full Text PDFETV6::RUNX1 Acute Lymphoblastic Leukemia: how much therapy is needed for cure?
Leukemia
July 2024
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Article Synopsis
- Recent trials show that over 95% of kids with a specific type of leukemia called ETV6::RUNX1 Acute Lymphoblastic Leukemia (ALL) live for at least 5 years after treatment.
- Scientists looked at different drug doses and their effects on patients from various studies to see how they compare and to better understand what treatment works best.
- The results suggest that some patients could possibly receive less intensive treatment while still being treated effectively, so future research should explore the possibility of giving less medicine.
B-cell precursor acute lymphoblastic leukemia elicits an interferon-α/β response in bone marrow-derived mesenchymal stroma.
Haematologica
July 2024
Dept. of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) can hijack the normal bone marrow microenvironment to create a leukemic niche which facilitates blast cell survival and promotes drug resistance. Bone marrow-derived mesenchymal stromal cells (MSC) mimic this protective environment in ex vivo co-cultures with leukemic cells obtained from children with newly diagnosed BCP-ALL. We examined the potential mechanisms of this protection by RNA sequencing of flow-sorted MSC after co-culture with BCP-ALL cells.
View Article and Find Full Text PDFOutcome and Prognostic Factors of Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory ETV6/RUNX1-Positive Acute Lymphoblastic Leukemia.
Acta Haematol
September 2024
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking-Tsinghua Center for Life Science, Research Unit of Key Technique for Diagnosis and Treatment of Hematologic Malignancies, Chinese Academic of Medical Sciences, Beijing, China.
Introduction: The role of haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) in pediatric patients with relapsed or refractory (R/R) ETV6/RUNX1-positive acute lymphoblastic leukemia (ALL) is unclear. This study aimed to identify prognostic factors and explore the role of haplo-HSCT in the treatment of ETV6/RUNX1-positive ALL.
Methods: We analyzed the clinical characteristics and treatment outcomes of 20 pediatric patients who were diagnosed with ETV6/RUNX1-positive ALL and received chemotherapy/chimeric antigen receptor T-cell bridged to haplo-HSCT between 2016 and 2021 at our institution.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!